Literature DB >> 15242470

Agreement of four competing guidelines on prevention of venous thromboembolism and comparison with observed physician practices: a cross-sectional study of 1,032 medical inpatients.

José Labarère1, Jean-Luc Bosson, Jean-François Bergmann, Nathalie Thilly.   

Abstract

OBJECTIVE: To assess the degree of agreement between four competing guidelines regarding the recommendation for prophylactic heparin therapy and to report to what extent actual practice agreed with or differed from the recommendations made before these guidelines were disseminated.
DESIGN: Four French guidelines were applied to data from a cross-sectional study conducted before their dissemination.
SETTING: Twenty-six medical units of a teaching and a nonteaching hospital. PATIENTS: One thousand thirty-two medical inpatients. MAIN MEASUREMENTS: Interguideline agreement rated by the kappa coefficient and percentage of patients receiving prophylactic heparin treatment.
RESULTS: The percentage of patients requiring prophylactic treatment ranged from 35.4% to 54.6% (overall kappa coefficient, 0.65 [0.63 to 0.68]), depending on the guideline. The four guidelines agreed in recommending prophylactic heparin treatment in 330 patients (32.0%). The corresponding rate of prophylactic treatment use was 57.0% (188/330). None of the guidelines recommended prophylactic heparin treatment in 385 patients (37.3%). The physicians did not order prophylactic treatment in 80.3% of these patients (309/385). The guidelines disagreed in recommending prophylactic treatment in 317 patients (30.7%). The corresponding rate of prophylactic treatment use was 32.8% (104/317).
CONCLUSION: The four guidelines agreed in 69.3% of patients but physician practices were already quite appropriate in these patients before the guidelines were disseminated. Active dissemination of the guidelines can be expected to improve physician practices in the treatment of these patients, but likely with limited impact. In contrast, the four guidelines disagreed in 30.7% of patients. Further clinical trials are needed in this subgroup of patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15242470      PMCID: PMC1492506          DOI: 10.1111/j.1525-1497.2004.30603.x

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  27 in total

Review 1.  Why don't physicians follow clinical practice guidelines? A framework for improvement.

Authors:  M D Cabana; C S Rand; N R Powe; A W Wu; M H Wilson; P A Abboud; H R Rubin
Journal:  JAMA       Date:  1999-10-20       Impact factor: 56.272

2.  Effect of specialty and nationality on panel judgments of the appropriateness of coronary revascularization: a pilot study.

Authors:  S J Bernstein; P Lázaro; K Fitch; M D Aguilar; J P Kahan
Journal:  Med Care       Date:  2001-05       Impact factor: 2.983

3.  Community-acquired pneumonia guidelines: much guidance, but not much evidence.

Authors:  M Woodhead
Journal:  Eur Respir J       Date:  2002-07       Impact factor: 16.671

4.  [Prevention of venous thromboembolism in a non-surgical medical ward. Proposed indications for low molecular weight heparin].

Authors:  J P Fagot; A Flahault; A Kanfer; G Benoit; A Bellanger; O Conort; I Durand-Zaleski; H Lioté; L Mangin; J Oliary; E Verdy; A Becker
Journal:  Presse Med       Date:  2000-01-15       Impact factor: 1.228

5.  Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.

Authors:  David Bergqvist; Giancarlo Agnelli; Alexander T Cohen; Amiram Eldor; Paul E Nilsson; Anne Le Moigne-Amrani; Flavia Dietrich-Neto
Journal:  N Engl J Med       Date:  2002-03-28       Impact factor: 91.245

6.  [Prophylactic prescription of low-molecular-weight heparin in the non-surgical setting: impact of recommendations].

Authors:  J P Fagot; A Flahault; M Fodil; A Kanfer; S Alamowitch; J P Haymann; I Lecomte; H Lioté; A Parrot; J Rossert; E Verdy; A Becker
Journal:  Presse Med       Date:  2001-02-10       Impact factor: 1.228

7.  Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials.

Authors:  J W Eikelboom; D J Quinlan; J D Douketis
Journal:  Lancet       Date:  2001-07-07       Impact factor: 79.321

8.  Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials.

Authors:  P Mismetti; S Laporte-Simitsidis; B Tardy; M Cucherat; A Buchmüller; D Juillard-Delsart; H Decousus
Journal:  Thromb Haemost       Date:  2000-01       Impact factor: 5.249

Review 9.  [Prevention of deep venous thrombosis in medical patients].

Authors:  J F Bergmann; I Mahe
Journal:  Ann Med Interne (Paris)       Date:  2000-05

10.  A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group.

Authors:  M M Samama; A T Cohen; J Y Darmon; L Desjardins; A Eldor; C Janbon; A Leizorovicz; H Nguyen; C G Olsson; A G Turpie; N Weisslinger
Journal:  N Engl J Med       Date:  1999-09-09       Impact factor: 91.245

View more
  1 in total

1.  Low-molecular-weight heparin prophylaxis of deep vein thrombosis for older patients with restricted mobility: propensity analyses of data from two multicentre, cross-sectional studies.

Authors:  José Labarère; Marie-Antoinette Sevestre; Joël Belmin; Annie Legagneux; Marie-Thérèse Barrellier; Hélène Thiel; Philippe Le Roux; Gilles Pernod; Jean-Luc Bosson
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.